Cargando…

Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study

SIMPLE SUMMARY: Over the last 5 years, immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of non-small cell lung cancer (NSCLC) as either monotherapy or in combination with chemo- and/or radiotherapy. However, despite these advances, outcome still remains poor for most patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaes, Rianne D. W., Reynders, Kobe, Sprooten, Jenny, Nevola, Kathleen T., Rouschop, Kasper M. A., Vooijs, Marc, Garg, Abhishek D., Lambrecht, Maarten, Hendriks, Lizza E. L., Rucevic, Marijana, De Ruysscher, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699057/ https://www.ncbi.nlm.nih.gov/pubmed/34944879 http://dx.doi.org/10.3390/cancers13246259

Ejemplares similares

Biomarkers of Radiotherapy-Induced Immunogenic Cell Death
por: Vaes, Rianne D. W., et al.
Publicado: (2021)

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
por: Berghmans, Thierry, et al.
Publicado: (2020)

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
por: Remon, Jordi, et al.
Publicado: (2022)

Shared decision-making for prophylactic cranial irradiation in extensive-stage small-cell lung cancer: an exploratory study
por: Ankolekar, Anshu, et al.
Publicado: (2021)

Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021)

Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC
por: Keek, Simon A., et al.
Publicado: (2022)

Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study
por: Degens, Juliette, et al.
Publicado: (2020)

First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020)

Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia
por: Cortiula, Francesco, et al.
Publicado: (2022)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy
por: Vanneste, Ben G. L., et al.
Publicado: (2021)

Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?
por: Peeters, Stephanie T. H., et al.
Publicado: (2021)

The Role of Lymphadenectomy in Early-Stage NSCLC
por: Manfredini, Beatrice, et al.
Publicado: (2023)

How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review
por: Remon, Jordi, et al.
Publicado: (2021)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue
por: Reynders, Kobe, et al.
Publicado: (2018)

Type I interferons and endoplasmic reticulum stress in health and disease
por: Sprooten, Jenny, et al.
Publicado: (2020)

Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
por: Sathiyapalan, Arani, et al.
Publicado: (2023)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

The Association of Gross Tumor Volume and Its Radiomics Features with Brain Metastases Development in Patients with Radically Treated Stage III Non-Small Cell Lung Cancer
por: Zeng, Haiyan, et al.
Publicado: (2023)

Staging of non-small cell lung cancer (NSCLC)
por: Rankin, S C
Publicado: (2006)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

The current treatment landscape in the UK for stage III NSCLC
por: Evison, Matthew
Publicado: (2020)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

Patient-Derived Cancer Organoids as Predictors of Treatment Response
por: Verduin, Maikel, et al.
Publicado: (2021)

A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
por: Sprooten, Jenny, et al.
Publicado: (2022)

The Independent Prognostic Effect of Lymph Node Dissection on Patients With Stage IA NSCLC With Different T Stages
por: Zhao, Dechang, et al.
Publicado: (2021)

Mechanisms of HIV Protein Degradation into Epitopes: Implications for Vaccine Design
por: Rucevic, Marijana, et al.
Publicado: (2014)

Radiation-Induced Lung Injury (RILI)
por: Giuranno, Lorena, et al.
Publicado: (2019)

Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases
por: Schoenmaekers, Janna J.A. O., et al.
Publicado: (2022)

The value of head imaging after PET-CT staging in NSCLC
por: Kamil, A, et al.
Publicado: (2015)

Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
por: Heineman, David J., et al.
Publicado: (2017)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
por: Vanmeerbeek, Isaure, et al.
Publicado: (2020)

Advances in radiological staging of non-small cell lung cancer (NSCLC)
por: Rankin, S C
Publicado: (2004)

Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC
por: Chen, Liangan, et al.
Publicado: (2011)

Risk factors of postoperative recurrences in patients with clinical stage I NSCLC
por: Chen, Ying-Yi, et al.
Publicado: (2014)

Stage and tissue-specific prognostic impact of miR-182 in NSCLC
por: Stenvold, Helge, et al.
Publicado: (2014)

Evaluate the outcome of pneumonectomy for stage III a-N2 NSCLC
por: Park, Sungjoon, et al.
Publicado: (2015)

Fully automated VMAT treatment planning for advanced-stage NSCLC patients
por: Della Gala, Giuseppe, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g457jm02sbjiut1gbvr36ub1ir